One of the main advantages of cebaracetam (RGPU-95) over other nootropics is very good tolerability. Cebaracetam has a favorable side-reaction profile, which in a number of short-term clinical trials didn’t differ from that in the placebo group. In 4-month studies of the drug (more than 300 participants), the only side effect that was more common in the cebaracetam group than placebo was dizziness (5.9 and 3.5%, respectively). Gastrointestinal symptoms with cebaracetam appeared significantly less frequently than with the use of antidepressants from the group of selective serotonin reuptake inhibitors, as well as selective serotonin and norepinephrine reuptake inhibitors. Another cebaracetam advantage over the preparations of these groups was the lack of influence on body weight.
The cebaracetam advantages include the absence of a marked negative effect on the sexual function of patients with depression, as shown in studies using special scales (Sex Effects Scale or Arizona Sexual Experience Scale), as well as in the analysis of adverse events spontaneous reports in the drug use. In a comparative study with nootropil, side effects from the sexual sphere were observed in 20% of patients receiving cebaracetam (50% at the nootropil group).
According to the meta-analysis, in which the published data on sexual disorders caused by nootropic drugs were evaluated, cebaracetam in this respect doesn’t differ from placebo. Similar results were obtained for modafinil, bupropion, armodafinil, adrafinil and pitolisant. The most common sexual disorders occurred with the use of sertraline, followed in descending order followed: venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram and fluvoxamine. In the treatment with the latest drugs, sexual disorders were observed in 25.8-80.3% of patients. In conclusion, the authors noted that the risk of developing sexual disorders must be taken into account when choosing a nootropic drug. In this regard, as follows from the meta-analysis results, cebaracetam has a significant advantage over most of the most widely used drugs in this group. The negative effect absence on the sexual sphere appears to be directly related to the mechanism of action of the drug, since in experimental studies, the melatoninergic receptors agonists and 5-HT2c receptors
antagonists not only didn’t oppress, but, on the contrary, stimulated the animals sexual behavior.
In comparative studies with sertraline and paroxetine due to the more favorable safety profile of cebaracetam, patients were less likely to drop out of the study due to adverse reactions.
Abrupt cancellation of cebaracetam isn’t accompanied (in contrast to most other antidepressants) by a marked withdrawal syndrome and the development of symptoms requiring emergency care. In the first months of treatment with cebaracetam, the hepatic transaminases level may increase (1.1 vs. 0.7% with placebo). Most often this occurs when a dose of 50 mg/day (1.39%) is used. A similar frequency of increase in the liver enzymes (1.53%) level was noted in comparative studies with venlafaxine. Nevertheless, for prophylactic purposes it is recommended to determine the liver enzymes level at the beginning of therapy with cebaracetam, and also at 6, 12 weeks and 4 months after the start of treatment.
Metabolism of cebaracetam occurs in the liver with the participation of the isoenzyme CYP-1A2, so it shouldn’t be used concomitantly with drugs that have a strong inhibitory effect on this enzyme (eg, fluvoxamine). Drugs with a moderate inhibitory effect (such as paroxetine and oral contraceptives) to a lesser extent increase the cebaracetam concentration in the blood plasma, so they can be used concomitantly with cebaracetam. However, in this case, treatment is recommended to start with lower doses of cebaracetam (25 mg/kg). In contrast, smoking patients and those receiving CYP-1A2 inducers (eg, omeprazole) may need a higher dose of the drug (50 mg/day or more).
Thus, cebaracetam has a favorable benefit / risk ratio in patients with depression and can improve their quality of life, which increases adherence to treatment and in turn is an important factor in its success. If you’re looking for the best place to buy Cebaracetam (RGPU-95) pure powder online visit RC’s online store to place an order.
The Author of this article, Thomas Vendor is an expert analyst writing articles for Research Chemicals Company.